Efficacy, long-term survival and safety of different PD-1 inhibitors plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis - Takeaways - MDSpire

Efficacy, long-term survival and safety of different PD-1 inhibitors plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis

  • By

  • Wen Sun

  • Yansha Liu

  • Hui Dong

  • Yun Huang

  • June 15, 2026

  • 0 min

Share

  • 1

    The study evaluates the efficacy, long-term survival, and safety of PD-1 inhibitors combined with chemotherapy in recurrent or metastatic nasopharyngeal carcinoma.

  • 2

    A systematic review and meta-analysis included 19 studies with 1459 patients, assessing outcomes like objective response rate and overall survival.

  • 3

    Toripalimab-based regimens showed the highest objective response rate and longest median progression-free survival of 21.4 months.

  • 4

    Tislelizumab plus chemotherapy yielded the best median overall survival of 45.3 months, while camrelizumab showed 34.5 months.

  • 5

    The pooled incidence of grade ≥3 treatment-related adverse events was 13%, indicating comparable safety profiles across all PD-1 inhibitors.

Original Source(s)

Efficacy, long-term survival and safety of different PD-1 inhibitors plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis

  • by Wen Sun, Yansha Liu, Hui Dong, Yun Huang

  • June 15, 2026

Related Content

Access to Specialty Cancer Care and Plan Disenrollment Among Medicare Beneficiaries

Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

Editorial: Innate lymphoid cells in cancer: volume II